Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector. 

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 21 August 2020.

Making headlines this time are two targeted acquisitions by big pharma, negative US FDA decisions and the outlook for the COVID-19-related business.

Stories mentioned in this episode:

(Also see "J&J Seeks Command Position In FcRn Space With Momenta Buyout" - Scrip, 19 Aug, 2020.)

(Also see "Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn" - Scrip, 17 Aug, 2020.)

(Also see "Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian" - Scrip, 19 Aug, 2020.)

(Also see "Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter" - Scrip, 19 Aug, 2020.)

(Also see "Can Moderna Meet Its COVID Vaccine Expectations?" - Scrip, 17 Aug, 2020.)


Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts